NOVO NORDISK A/S-B (NOV.DE) Fundamental Analysis & Valuation
FRA:NOV • DK0062498333
Current stock price
36.21 EUR
+2.2 (+6.48%)
Last:
This NOV.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. NOV.DE Profitability Analysis
1.1 Basic Checks
- In the past year NOV was profitable.
- NOV had a positive operating cash flow in the past year.
- NOV had positive earnings in each of the past 5 years.
- In the past 5 years NOV always reported a positive cash flow from operatings.
1.2 Ratios
- NOV has a better Return On Assets (18.87%) than 100.00% of its industry peers.
- NOV has a better Return On Equity (52.79%) than 93.88% of its industry peers.
- NOV's Return On Invested Capital of 30.79% is amongst the best of the industry. NOV outperforms 95.92% of its industry peers.
- NOV had an Average Return On Invested Capital over the past 3 years of 43.61%. This is significantly above the industry average of 14.21%.
- The last Return On Invested Capital (30.79%) for NOV is well below the 3 year average (43.61%), which needs to be investigated, but indicates that NOV had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROIC | 30.79% |
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
1.3 Margins
- NOV has a better Profit Margin (33.14%) than 100.00% of its industry peers.
- NOV's Profit Margin has been stable in the last couple of years.
- NOV's Operating Margin of 41.30% is amongst the best of the industry. NOV outperforms 95.92% of its industry peers.
- In the last couple of years the Operating Margin of NOV has remained more or less at the same level.
- With an excellent Gross Margin value of 80.98%, NOV belongs to the best of the industry, outperforming 85.71% of the companies in the same industry.
- NOV's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% |
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
2. NOV.DE Health Analysis
2.1 Basic Checks
- The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so NOV is creating value.
- The number of shares outstanding for NOV remains at a similar level compared to 1 year ago.
- The number of shares outstanding for NOV has been increased compared to 5 years ago.
- The debt/assets ratio for NOV is higher compared to a year ago.
2.2 Solvency
- An Altman-Z score of 3.33 indicates that NOV is not in any danger for bankruptcy at the moment.
- Looking at the Altman-Z score, with a value of 3.33, NOV is in line with its industry, outperforming 53.06% of the companies in the same industry.
- The Debt to FCF ratio of NOV is 4.52, which is a neutral value as it means it would take NOV, 4.52 years of fcf income to pay off all of its debts.
- NOV has a Debt to FCF ratio of 4.52. This is comparable to the rest of the industry: NOV outperforms 53.06% of its industry peers.
- A Debt/Equity ratio of 0.61 indicates that NOV is somewhat dependend on debt financing.
- NOV has a Debt to Equity ratio (0.61) which is in line with its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Altman-Z | 3.33 |
ROIC/WACC4.91
WACC6.27%
2.3 Liquidity
- NOV has a Current Ratio of 0.80. This is a bad value and indicates that NOV is not financially healthy enough and could expect problems in meeting its short term obligations.
- NOV's Current ratio of 0.80 is on the low side compared to the rest of the industry. NOV is outperformed by 81.63% of its industry peers.
- A Quick Ratio of 0.57 indicates that NOV may have some problems paying its short term obligations.
- NOV's Quick ratio of 0.57 is on the low side compared to the rest of the industry. NOV is outperformed by 83.67% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 |
3. NOV.DE Growth Analysis
3.1 Past
- NOV shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 1.77%.
- Measured over the past years, NOV shows a very strong growth in Earnings Per Share. The EPS has been growing by 20.66% on average per year.
- Looking at the last year, NOV shows a small growth in Revenue. The Revenue has grown by 6.43% in the last year.
- Measured over the past years, NOV shows a quite strong growth in Revenue. The Revenue has been growing by 19.48% on average per year.
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%
3.2 Future
- NOV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.93% yearly.
- NOV is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.35% yearly.
EPS Next Y-7.2%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
EPS Next 5Y3.93%
Revenue Next Year-6.27%
Revenue Next 2Y-1.41%
Revenue Next 3Y1.06%
Revenue Next 5Y3.35%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. NOV.DE Valuation Analysis
4.1 Price/Earnings Ratio
- The Price/Earnings ratio is 11.76, which indicates a very decent valuation of NOV.
- Based on the Price/Earnings ratio, NOV is valued a bit cheaper than the industry average as 77.55% of the companies are valued more expensively.
- When comparing the Price/Earnings ratio of NOV to the average of the S&P500 Index (26.77), we can say NOV is valued rather cheaply.
- With a Price/Forward Earnings ratio of 12.66, NOV is valued correctly.
- Based on the Price/Forward Earnings ratio, NOV is valued a bit cheaper than the industry average as 75.51% of the companies are valued more expensively.
- Compared to an average S&P500 Price/Forward Earnings ratio of 21.75, NOV is valued a bit cheaper.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.76 | ||
| Fwd PE | 12.66 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, NOV is valued cheaply inside the industry as 89.80% of the companies are valued more expensively.
- Based on the Price/Free Cash Flow ratio, NOV is valued a bit more expensive than 63.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 31.64 | ||
| EV/EBITDA | 6.82 |
4.3 Compensation for Growth
- NOV has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.57
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
5. NOV.DE Dividend Analysis
5.1 Amount
- NOV has a Yearly Dividend Yield of 4.74%, which is a nice return.
- In the last 3 months the price of NOV has falen by -27.19%. A price decline artificially increases the dividend yield. It may be a sign investors do not expect the dividend to last.
- NOV's Dividend Yield is rather good when compared to the industry average which is at 1.96. NOV pays more dividend than 83.67% of the companies in the same industry.
- NOV's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.74% |
5.2 History
- The dividend of NOV is nicely growing with an annual growth rate of 19.05%!
Dividend Growth(5Y)19.05%
Div Incr Years1
Div Non Decr Years1
5.3 Sustainability
- NOV pays out 50.53% of its income as dividend. This is a bit on the high side, but may be sustainable.
- The dividend of NOV is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP50.53%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
NOV.DE Fundamentals: All Metrics, Ratios and Statistics
FRA:NOV (4/30/2026, 7:00:00 PM)
36.21
+2.2 (+6.48%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)02-03 2026-02-03/amc
Earnings (Next)05-06 2026-05-06
Inst Owners31.87%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap122.76B
Revenue(TTM)309.06B
Net Income(TTM)102.43B
Analysts67.57
Price Target42.87 (18.39%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 4.74% |
Yearly Dividend1.56
Dividend Growth(5Y)19.05%
DP50.53%
Div Incr Years1
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-2.82%
Min EPS beat(2)-7.04%
Max EPS beat(2)1.39%
EPS beat(4)2
Avg EPS beat(4)-0.71%
Min EPS beat(4)-7.04%
Max EPS beat(4)3.94%
EPS beat(8)5
Avg EPS beat(8)1.01%
EPS beat(12)8
Avg EPS beat(12)1.47%
EPS beat(16)11
Avg EPS beat(16)1.68%
Revenue beat(2)1
Avg Revenue beat(2)-1.06%
Min Revenue beat(2)-3.19%
Max Revenue beat(2)1.07%
Revenue beat(4)1
Avg Revenue beat(4)-0.92%
Min Revenue beat(4)-3.19%
Max Revenue beat(4)1.07%
Revenue beat(8)3
Avg Revenue beat(8)0.15%
Revenue beat(12)6
Avg Revenue beat(12)0.52%
Revenue beat(16)9
Avg Revenue beat(16)0.84%
PT rev (1m)-13.2%
PT rev (3m)-19.72%
EPS NQ rev (1m)10.83%
EPS NQ rev (3m)15.44%
EPS NY rev (1m)-3.37%
EPS NY rev (3m)-6.18%
Revenue NQ rev (1m)2.26%
Revenue NQ rev (3m)-37.39%
Revenue NY rev (1m)-1.7%
Revenue NY rev (3m)-6.51%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 11.76 | ||
| Fwd PE | 12.66 | ||
| P/S | 2.97 | ||
| P/FCF | 31.64 | ||
| P/OCF | 7.7 | ||
| P/B | 4.73 | ||
| P/tB | 14.33 | ||
| EV/EBITDA | 6.82 |
EPS(TTM)3.08
EY8.51%
EPS(NY)2.86
Fwd EY7.9%
FCF(TTM)1.14
FCFY3.16%
OCF(TTM)4.7
OCFY12.99%
SpS12.2
BVpS7.66
TBVpS2.53
PEG (NY)N/A
PEG (5Y)0.57
Graham Number23.0412 (-36.37%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.87% | ||
| ROE | 52.79% | ||
| ROCE | 39.01% | ||
| ROIC | 30.79% | ||
| ROICexc | 33.56% | ||
| ROICexgc | 59.2% | ||
| OM | 41.3% | ||
| PM (TTM) | 33.14% | ||
| GM | 80.98% | ||
| FCFM | 9.38% |
ROA(3y)22.39%
ROA(5y)22.95%
ROE(3y)67.23%
ROE(5y)67.14%
ROIC(3y)43.61%
ROIC(5y)44.74%
ROICexc(3y)50.94%
ROICexc(5y)53.03%
ROICexgc(3y)100.46%
ROICexgc(5y)105.49%
ROCE(3y)55.75%
ROCE(5y)58.53%
ROICexgc growth 3Y-22.89%
ROICexgc growth 5Y-7.78%
ROICexc growth 3Y-18.13%
ROICexc growth 5Y-11.63%
OM growth 3Y-1.15%
OM growth 5Y-0.81%
PM growth 3Y1.84%
PM growth 5Y-0.03%
GM growth 3Y-1.18%
GM growth 5Y-0.61%
F-Score5
Asset Turnover0.57
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.61 | ||
| Debt/FCF | 4.52 | ||
| Debt/EBITDA | 0.79 | ||
| Cap/Depr | 409.94% | ||
| Cap/Sales | 29.16% | ||
| Interest Coverage | 37.34 | ||
| Cash Conversion | 79.59% | ||
| Profit Quality | 28.3% | ||
| Current Ratio | 0.8 | ||
| Quick Ratio | 0.57 | ||
| Altman-Z | 3.33 |
F-Score5
WACC6.27%
ROIC/WACC4.91
Cap/Depr(3y)363.9%
Cap/Depr(5y)282.93%
Cap/Sales(3y)21.19%
Cap/Sales(5y)15.43%
Profit Quality(3y)60.31%
Profit Quality(5y)79.23%
High Growth Momentum
Growth
EPS 1Y (TTM)1.77%
EPS 3Y23.52%
EPS 5Y20.66%
EPS Q2Q%-4.73%
EPS Next Y-7.2%
EPS Next 2Y-3.65%
EPS Next 3Y0.38%
EPS Next 5Y3.93%
Revenue 1Y (TTM)6.43%
Revenue growth 3Y20.43%
Revenue growth 5Y19.48%
Sales Q2Q%-7.63%
Revenue Next Year-6.27%
Revenue Next 2Y-1.41%
Revenue Next 3Y1.06%
Revenue Next 5Y3.35%
EBIT growth 1Y-4.76%
EBIT growth 3Y19.04%
EBIT growth 5Y18.51%
EBIT Next Year8.72%
EBIT Next 3Y6.24%
EBIT Next 5Y8.11%
FCF growth 1Y-58.38%
FCF growth 3Y-23.26%
FCF growth 5Y-0.6%
OCF growth 1Y-1.54%
OCF growth 3Y14.72%
OCF growth 5Y18.05%
NOVO NORDISK A/S-B / NOV.DE Fundamental Analysis FAQ
What is the fundamental rating for NOV stock?
ChartMill assigns a fundamental rating of 6 / 10 to NOV.DE.
Can you provide the valuation status for NOVO NORDISK A/S-B?
ChartMill assigns a valuation rating of 5 / 10 to NOVO NORDISK A/S-B (NOV.DE). This can be considered as Fairly Valued.
How profitable is NOVO NORDISK A/S-B (NOV.DE) stock?
NOVO NORDISK A/S-B (NOV.DE) has a profitability rating of 9 / 10.
What is the financial health of NOVO NORDISK A/S-B (NOV.DE) stock?
The financial health rating of NOVO NORDISK A/S-B (NOV.DE) is 3 / 10.
Can you provide the dividend sustainability for NOV stock?
The dividend rating of NOVO NORDISK A/S-B (NOV.DE) is 7 / 10 and the dividend payout ratio is 50.53%.